Mattia Migliari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mattia Migliari has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Nicola Leone
Unit of Vascular Surgery, Department of Nephrological, Cardiac and Vascular Diseases Azienda Ospedaliero‐Universitaria of Modena Modena Italy
11 shared publications Stefano Gennai
Department of Vascular Surgery, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy
11 shared publicationsRoberto Silingardi
Unit of Vascular Surgery, Department of Nephrological, Cardiac and Vascular Diseases Azienda Ospedaliero‐Universitaria of Modena Modena Italy
10 shared publications- Francesco Andreoli
Division of Vascular Surgery and Angiology, Centro Vascolare Ticino, Ente Ospedaliero Cantonale, CH-6900 Lugano, Switzerland
9 shared publications - Roberto Silingardi
Department of Vascular Surgery, Ospedale Civile Sant'Agostino-Estense, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy
9 shared publications - Francesco Speziale
Vascular and Endovascular Surgery Unit, Department of Surgery Paride Stefanini, Sapienza University of Rome, Rome, Italy
6 shared publications
Latest Publications
- Open Access
Cross‐Sectional Study of the PREValence of Erectile DysfunctIon in the Arteriopathic Population (PREVEDI)
Background: Although the association between erectile dysfunction (ED) and cardiovascular disease is well established, its prevalence in patients with atherosclerosis remains poorly defined. Objectives: To evaluate ED prevalence, severity, and associated risk factors (RFs) in patients with atherosclerotic disease. Materials and Methods: This single‐centre, cross‐sectional, non‐randomised observational study included male patients referred to a vascular surgery service with documented atherosclerotic disease. Erectile function was assessed using the International Index of Erectile Function‐15 questionnaire, and RFs were analysed using univariable and multivariable regression models. Results: A total of 162 patients were enrolled (mean age, 70.1 ± 8.6 years); ED was present in 93.8%, with severe ED observed in 62.3%. Multivariable analysis confirmed age as a significant RF for ED, particularly > 75 years, while age, diabetes mellitus, and subjective ED duration were significantly associated with greater severity. Discussion: The high prevalence of ED supports its role as a manifestation of systemic vascular disease linked to endothelial dysfunction and diffuse atherosclerosis. Conclusion: ED is highly prevalent among patients with clinically overt atherosclerotic disease requiring vascular surgery referral, and may represent a marker of systemic vascular pathology. Routine assessment of sexual function may improve cardiovascular risk stratification and preventive management.
Open AccessCross‐Sectional Study of the PREValence of Erectile DysfunctIon in the Arteriopathic Population (PREVEDI)
Background: Although the association between erectile dysfunction (ED) and cardiovascular disease is well established, its prevalence in patients with atherosclerosis remains poorly defined. Objectives: To evaluate ED prevalence, severity, and associated risk factors (RFs) in patients with atherosclerotic disease. Materials and Methods: This single‐centre, cross‐sectional, non‐randomised observational study included male patients referred to a vascular surgery service with documented atherosclerotic disease. Erectile function was assessed using the International Index of Erectile Function‐15 questionnaire, and RFs were analysed using univariable and multivariable regression models. Results: A total of 162 patients were enrolled (mean age, 70.1 ± 8.6 years); ED was present in 93.8%, with severe ED observed in 62.3%. Multivariable analysis confirmed age as a significant RF for ED, particularly > 75 years, while age, diabetes mellitus, and subjective ED duration were significantly associated with greater severity. Discussion: The high prevalence of ED supports its role as a manifestation of systemic vascular disease linked to endothelial dysfunction and diffuse atherosclerosis. Conclusion: ED is highly prevalent among patients with clinically overt atherosclerotic disease requiring vascular surgery referral, and may represent a marker of systemic vascular pathology. Routine assessment of sexual function may improve cardiovascular risk stratification and preventive management.
- 26 January 2026
- Published by SAGE Publications in Journal of Endovascular Therapy
Anatomical Viability of the “Hector Multibranched Thoracic Stent-Graft System” and Connecting Stent for Endovascular Aortic Arch Repair
Introduction: Endovascular repair of the aortic arch has emerged as an alternative to open surgery, particularly for high-risk and elderly patients. While multibranched endografts have demonstrated technical success, anatomical suitability remains a key limiting factor, especially given the variability of arch anatomy. The aim of the present study is to evaluate the suitability of the Hector multibranch device in a cohort of patients who underwent endovascular treatment for aortic arch’s lesions. Methods: A total of 539 patients were treated between 1999 and 2024, with 79 included in a single-center, retrospective, preclinical study. The suitability for device and its connecting stent was defined according to the manufacturer’s instructions for use. Extended suitability was also evaluated, including patients excluded for limiting anatomical criteria. Secondary outcomes were suitable and non-suitable patients’ comparison, exclusion causes analysis, and anatomical characteristics associated with suitability. A logistic regression model assessed associations between baseline and non-suitability. Results: A total of 50 patients (63.2%) were suitable for implantation, raising to 54 (68.4%) by using other available bridging stents. Approximately half of the eligible patients could have been treated using 14 configurations for the analyzed device. The left common carotid artery bridging stent was appropriate for all suitable patients, while the appropriateness rate for the left subclavian artery stent was 92.6%. The odds of non-feasibility increased with proximal landing zone shortening (OR=1.05, p=0.015), whereas each additional millimeter in BCT length increased the odds of suitability by 6% (OR=1.06, p=0.046). Conclusions: The Hector Stent Graft system coupled with commercially available bridging stents for supra-aortic trunks proved to be feasible for more than two-thirds of patients previously subjected to an endovascular treatment for aortic arch pathologies. The left common carotid artery bridging stent was suitable for all patients, while the one for the left subclavian artery was adequate for 9 out of 10 cases. Clinical Impact: The Hector™ Stent Graft system shows high anatomical feasibility for endovascular aortic arch repair, with broad applicability using limited configurations. Its design may help minimize supra-aortic-trunks manipulation and facilitate safer, more streamlined procedures to treat the aortic arch pathologies in a complete endovascular fashion.
- 26 January 2026
- Published by SAGE Publications in Journal of Endovascular Therapy
Anatomical Viability of the “Hector Multibranched Thoracic Stent-Graft System” and Connecting Stent for Endovascular Aortic Arch Repair
Introduction: Endovascular repair of the aortic arch has emerged as an alternative to open surgery, particularly for high-risk and elderly patients. While multibranched endografts have demonstrated technical success, anatomical suitability remains a key limiting factor, especially given the variability of arch anatomy. The aim of the present study is to evaluate the suitability of the Hector multibranch device in a cohort of patients who underwent endovascular treatment for aortic arch’s lesions. Methods: A total of 539 patients were treated between 1999 and 2024, with 79 included in a single-center, retrospective, preclinical study. The suitability for device and its connecting stent was defined according to the manufacturer’s instructions for use. Extended suitability was also evaluated, including patients excluded for limiting anatomical criteria. Secondary outcomes were suitable and non-suitable patients’ comparison, exclusion causes analysis, and anatomical characteristics associated with suitability. A logistic regression model assessed associations between baseline and non-suitability. Results: A total of 50 patients (63.2%) were suitable for implantation, raising to 54 (68.4%) by using other available bridging stents. Approximately half of the eligible patients could have been treated using 14 configurations for the analyzed device. The left common carotid artery bridging stent was appropriate for all suitable patients, while the appropriateness rate for the left subclavian artery stent was 92.6%. The odds of non-feasibility increased with proximal landing zone shortening (OR=1.05, p=0.015), whereas each additional millimeter in BCT length increased the odds of suitability by 6% (OR=1.06, p=0.046). Conclusions: The Hector Stent Graft system coupled with commercially available bridging stents for supra-aortic trunks proved to be feasible for more than two-thirds of patients previously subjected to an endovascular treatment for aortic arch pathologies. The left common carotid artery bridging stent was suitable for all patients, while the one for the left subclavian artery was adequate for 9 out of 10 cases. Clinical Impact: The Hector™ Stent Graft system shows high anatomical feasibility for endovascular aortic arch repair, with broad applicability using limited configurations. Its design may help minimize supra-aortic-trunks manipulation and facilitate safer, more streamlined procedures to treat the aortic arch pathologies in a complete endovascular fashion.
- Open Access
- 14 November 2025
- Published by Wiley in International Wound Journal
- Vol. 22 (11) , e70784
Clinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation ( SEFFIDiFA Trial)
Diabetic foot ulcers (DFUs) are severe complications of diabetes that often lead to major amputations. Despite care advancements, approximately 50% of minor amputations do not heal, resulting in major amputations and increased mortality. This study evaluated the effectiveness of adipose‐derived stem cells (ASCs) obtained through superficial enhanced fluid fat injection (SEFFI) in improving healing rates after minor amputations in DFUs. It was a prospective, single‐arm, observational cohort study. The patients were monitored for half a year using monthly assessments. The primary endpoint was the healing rate of the amputation stumps after minor amputations coupled with ASC injections. Secondary endpoints included safety, feasibility, adverse events and analysis of variables associated with healing including the analysis of the injected mesenchymal adipose stem cell populations. Of the 256 screened patients, 40 were enrolled. At 6 months, 55% of the treated stumps had healed completely. The median healing time was 69 days. Technical success was achieved in all cases without device‐related complications. Multivariable Cox models identified haemodialysis, opioid use and the injected number of CD45 ‐positive cells as risk factors for healing failure. CD73 expression was positively associated with healing. The SEFFIDiFA trial demonstrated a promising 69% healing probability at 6 months post‐amputation. This minimally invasive approach showed a higher healing rate with fewer complications. This study supports the potential of ASCs in enhancing wound healing in DFUs and highlights the importance of CD73 expression for successful outcomes. Further research is warranted to validate these findings and optimise the technique.
- 14 November 2025
- Published by Wiley in International Wound Journal
- Vol. 22 (11) , e70784
Open AccessClinical Outcomes and Characterisation of the Autologous Adipose Tissue Harvested With Superficial Enhanced Fluid Fat Injection Method for Treatment of Diabetic Foot Ulcer Undergoing Minor Amputation ( SEFFIDiFA Trial)
Diabetic foot ulcers (DFUs) are severe complications of diabetes that often lead to major amputations. Despite care advancements, approximately 50% of minor amputations do not heal, resulting in major amputations and increased mortality. This study evaluated the effectiveness of adipose‐derived stem cells (ASCs) obtained through superficial enhanced fluid fat injection (SEFFI) in improving healing rates after minor amputations in DFUs. It was a prospective, single‐arm, observational cohort study. The patients were monitored for half a year using monthly assessments. The primary endpoint was the healing rate of the amputation stumps after minor amputations coupled with ASC injections. Secondary endpoints included safety, feasibility, adverse events and analysis of variables associated with healing including the analysis of the injected mesenchymal adipose stem cell populations. Of the 256 screened patients, 40 were enrolled. At 6 months, 55% of the treated stumps had healed completely. The median healing time was 69 days. Technical success was achieved in all cases without device‐related complications. Multivariable Cox models identified haemodialysis, opioid use and the injected number of CD45 ‐positive cells as risk factors for healing failure. CD73 expression was positively associated with healing. The SEFFIDiFA trial demonstrated a promising 69% healing probability at 6 months post‐amputation. This minimally invasive approach showed a higher healing rate with fewer complications. This study supports the potential of ASCs in enhancing wound healing in DFUs and highlights the importance of CD73 expression for successful outcomes. Further research is warranted to validate these findings and optimise the technique.
- 25 March 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (5) , 2421-2428
Risk Factors and Perioperative Outcomes of Postimplantation Syndrome After Thoracic Endovascular Aortic Repair
Objective: Postimplantation syndrome (PIS) is a systemic inflammatory response that occurs following abdominal endovascular aortic repair (EVAR) and thoracic EVAR (TEVAR). The main outcome was to individuate the incidence and risk factors of PIS after TEVAR. Its impact on the length of stay and clinical outcomes were secondary objectives. Materials and Methods: Three hundred sixty-nine consecutive TEVAR procedures performed between February 2010 and November 2022 were included in this retrospective cohort, observational, single-center study. Patients with proximal landing in zones 0 to 5 were enrolled. Data on comorbidities, previous aortic surgery and morphology, thoracic aorta coverage, stent-graft composition, intraoperative variables, and postoperative outcomes were collected. White blood cell (WBC) and C-reactive protein (CRP) serum levels were recorded preoperatively and 48 hours after TEVAR. PIS was defined as the concomitant presence of fever (tympanic temperature ≥38.0°C), CRP serum level >0.7 mg/dl and evidence of pleural effusion on postoperative chest radiograph. Results: PIS incidence in our cohort was 26.8%. PIS patients presented with a higher rate of hyperlipidemia (56.6% vs 44.8%, p = 0.045) than non-PIS patients. Stent-graft composition did not play a relevant role in eliciting PIS. PIS was a statistically significant factor in prolonging patients’ stay (median 16.0 days vs 8.0 days, p < 0.001, PIS and non-PIS patients). Thoracic aortic coverage >150 mm (Odds Ratio (OR) 4.7, p = 0.004), coronary artery disease (OR 2.1, p = 0.028), and preoperative WBC count (OR 1.1, p = 0.047) were identified as risk factors for PIS, whereas previous aortic surgery (OR 0.5, p = 0.05) was highlighted as a protective factor. Thoracic aortic coverage was a significant risk factor for increased WBC and CRP levels (p < 0.001). Conclusion: PIS incidence was 26.8% in our cohort. Thoracic aortic coverage, coronary artery disease, and preoperative WBC count were identified as risk factors for PIS after TEVAR, whereas previous aortic surgery was found to be a protective factor. PIS also appeared to have a significant impact on length of stay. Clinical Impact: This study identified a significant occurrence of post-implantation syndrome (PIS) following TEVAR, affecting over 25% of patients and adversely affecting the duration of hospital stay. Stent graft material did not seem to influence the incidence of PIS. Thoracic aortic coverage, coronary artery disease, and preoperative white blood cell (WBC) count have been identified as risk factors, whereas previous aortic surgery has been found to serve as a protective factor, representing a novel finding in the literature. Further research is warranted to ascertain strategies for mitigating the incidence of PIS, considering the risk factors identified in both current and prior studies. In addition, it is necessary to evaluate the potential implementation of preoperative prophylactic therapy for PIS in patients undergoing TEVAR.
- 25 March 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (5) , 2421-2428
Risk Factors and Perioperative Outcomes of Postimplantation Syndrome After Thoracic Endovascular Aortic Repair
Objective: Postimplantation syndrome (PIS) is a systemic inflammatory response that occurs following abdominal endovascular aortic repair (EVAR) and thoracic EVAR (TEVAR). The main outcome was to individuate the incidence and risk factors of PIS after TEVAR. Its impact on the length of stay and clinical outcomes were secondary objectives. Materials and Methods: Three hundred sixty-nine consecutive TEVAR procedures performed between February 2010 and November 2022 were included in this retrospective cohort, observational, single-center study. Patients with proximal landing in zones 0 to 5 were enrolled. Data on comorbidities, previous aortic surgery and morphology, thoracic aorta coverage, stent-graft composition, intraoperative variables, and postoperative outcomes were collected. White blood cell (WBC) and C-reactive protein (CRP) serum levels were recorded preoperatively and 48 hours after TEVAR. PIS was defined as the concomitant presence of fever (tympanic temperature ≥38.0°C), CRP serum level >0.7 mg/dl and evidence of pleural effusion on postoperative chest radiograph. Results: PIS incidence in our cohort was 26.8%. PIS patients presented with a higher rate of hyperlipidemia (56.6% vs 44.8%, p = 0.045) than non-PIS patients. Stent-graft composition did not play a relevant role in eliciting PIS. PIS was a statistically significant factor in prolonging patients’ stay (median 16.0 days vs 8.0 days, p < 0.001, PIS and non-PIS patients). Thoracic aortic coverage >150 mm (Odds Ratio (OR) 4.7, p = 0.004), coronary artery disease (OR 2.1, p = 0.028), and preoperative WBC count (OR 1.1, p = 0.047) were identified as risk factors for PIS, whereas previous aortic surgery (OR 0.5, p = 0.05) was highlighted as a protective factor. Thoracic aortic coverage was a significant risk factor for increased WBC and CRP levels (p < 0.001). Conclusion: PIS incidence was 26.8% in our cohort. Thoracic aortic coverage, coronary artery disease, and preoperative WBC count were identified as risk factors for PIS after TEVAR, whereas previous aortic surgery was found to be a protective factor. PIS also appeared to have a significant impact on length of stay. Clinical Impact: This study identified a significant occurrence of post-implantation syndrome (PIS) following TEVAR, affecting over 25% of patients and adversely affecting the duration of hospital stay. Stent graft material did not seem to influence the incidence of PIS. Thoracic aortic coverage, coronary artery disease, and preoperative white blood cell (WBC) count have been identified as risk factors, whereas previous aortic surgery has been found to serve as a protective factor, representing a novel finding in the literature. Further research is warranted to ascertain strategies for mitigating the incidence of PIS, considering the risk factors identified in both current and prior studies. In addition, it is necessary to evaluate the potential implementation of preoperative prophylactic therapy for PIS in patients undergoing TEVAR.
- 17 March 2025
- Published by SAGE Publications in Scandinavian Journal of Surgery
Visceral artery aneurysms: A shred of light on rare entities
Visceral artery aneurysms (VAAs) and pseudoaneurysms are rare but clinically significant vascular pathologies with potentially fatal complications including rupture. VAAs are often asymptomatic and frequently discovered incidentally during imaging performed for unrelated reasons. Their pathophysiology, clinical presentation, and management vary based on the etiology, anatomical location, and patient-specific factors. The prognosis for conservatively managed VAAs is generally favorable, with slow growth rates and low rupture risks. However, pseudoaneurysms, often associated with trauma or pancreatitis, carry a much higher rupture risk and typically require early intervention, regardless of size. Endovascular techniques have progressively replaced open surgery as the preferred treatment approach due to lower complication rates and comparable long-term outcomes. However, current knowledge is biased by the scarcity of high-quality evidence regarding the natural history, rupture risk, and optimal management of VAAs and pseudoaneurysms, largely due to the rarity of these conditions. Consequently, different international societies have provided recommendations with low strength and, in some cases, conflicting indications.
- 17 March 2025
- Published by SAGE Publications in Scandinavian Journal of Surgery
Visceral artery aneurysms: A shred of light on rare entities
Visceral artery aneurysms (VAAs) and pseudoaneurysms are rare but clinically significant vascular pathologies with potentially fatal complications including rupture. VAAs are often asymptomatic and frequently discovered incidentally during imaging performed for unrelated reasons. Their pathophysiology, clinical presentation, and management vary based on the etiology, anatomical location, and patient-specific factors. The prognosis for conservatively managed VAAs is generally favorable, with slow growth rates and low rupture risks. However, pseudoaneurysms, often associated with trauma or pancreatitis, carry a much higher rupture risk and typically require early intervention, regardless of size. Endovascular techniques have progressively replaced open surgery as the preferred treatment approach due to lower complication rates and comparable long-term outcomes. However, current knowledge is biased by the scarcity of high-quality evidence regarding the natural history, rupture risk, and optimal management of VAAs and pseudoaneurysms, largely due to the rarity of these conditions. Consequently, different international societies have provided recommendations with low strength and, in some cases, conflicting indications.
- 22 May 2024
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (1) , 377-390
Type III Endoleak Incidence and Outcomes in Endovascular Aortic Repair: Comparison of Anatomical and Proximal Fixation Devices
Purpose: To evaluate the influence of endograft fixation type on the incidence, treatment, and outcomes of type III endoleaks (TIIIELs). Materials and methods: Abdominal aortic aneurysms (AAAs) treated with bifurcated endografts between 1994 and 2020 were prospectively collected and reviewed. The endograft included were classified as “Anatomical Fixation” (AF) (Powerlink [Endologix] and AFX [Endologix]) or “Proximal Fixation” (PF). The primary outcome was the incidence of TIIIEL over time, stratified by fixation type. Secondary outcomes included between-group comparisons of baseline characteristics, intraoperative details during TIIIEL correction, and survival analysis after TIIIEL diagnosis. Results: A total of 2065 endovascular aneurysm repairs were performed: 872 (42.2%) with AF and 1193 (57.8%) with PF devices. The estimated incidence of TIIIEL at 1, 5, and 10 years was 0.4%, 4.2%, and 7.3%, and 0.5%, 3.2%, and 4.6% for AF and PF, respectively (p=0.157), and fixation type was not associated with TIIIEL development in the competing risk regression model (p=0.101). The cumulative overall survival rate in patients diagnosed with TIIIEL did not differ significantly between the groups (p=0.077). The rate of recurrent TIIIELs was significantly lower in the AF group (7.1% vs 22.7%; p=0.044); however, no significant difference was found in secondary reintervention between the two groups (11.9% vs 27.3%, p=0.074). Patients with angulated and calcified aortic neck (SHR 3.4, 95% CI 1.2–9.6, p=0.022) and larger aneurysms (SHR 1.2; 95% CI 1.1–1.3; p<0.001) had a higher risk of TIIIEL. Likewise, the use of three or more endograft components increased the risk of TIIIEL by 3.1 times (SHR 3.1; 95% CI 1.7–5.4; p<0.001). Conclusions: The occurrence of TIIIELs was not affected by the type of endograft fixation. For larger abdominal aortic aneurysms (AAAs) and aneurysms with angulated and calcified aortic necks, there is a higher likelihood of developing TIIIELs during follow-up, regardless of the endograft type used. Clinical Impact: The type of fixation does not influence the incidence of TIII ELs. EVAR in larger AAAs and aneurysms with angulated and calcified aortic necks have a higher risk of developing TIII EL. Moreover, the risk of TIII EL is considerably increased by the use of three or more modular components.
- 22 May 2024
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (1) , 377-390
Type III Endoleak Incidence and Outcomes in Endovascular Aortic Repair: Comparison of Anatomical and Proximal Fixation Devices
Purpose: To evaluate the influence of endograft fixation type on the incidence, treatment, and outcomes of type III endoleaks (TIIIELs). Materials and methods: Abdominal aortic aneurysms (AAAs) treated with bifurcated endografts between 1994 and 2020 were prospectively collected and reviewed. The endograft included were classified as “Anatomical Fixation” (AF) (Powerlink [Endologix] and AFX [Endologix]) or “Proximal Fixation” (PF). The primary outcome was the incidence of TIIIEL over time, stratified by fixation type. Secondary outcomes included between-group comparisons of baseline characteristics, intraoperative details during TIIIEL correction, and survival analysis after TIIIEL diagnosis. Results: A total of 2065 endovascular aneurysm repairs were performed: 872 (42.2%) with AF and 1193 (57.8%) with PF devices. The estimated incidence of TIIIEL at 1, 5, and 10 years was 0.4%, 4.2%, and 7.3%, and 0.5%, 3.2%, and 4.6% for AF and PF, respectively (p=0.157), and fixation type was not associated with TIIIEL development in the competing risk regression model (p=0.101). The cumulative overall survival rate in patients diagnosed with TIIIEL did not differ significantly between the groups (p=0.077). The rate of recurrent TIIIELs was significantly lower in the AF group (7.1% vs 22.7%; p=0.044); however, no significant difference was found in secondary reintervention between the two groups (11.9% vs 27.3%, p=0.074). Patients with angulated and calcified aortic neck (SHR 3.4, 95% CI 1.2–9.6, p=0.022) and larger aneurysms (SHR 1.2; 95% CI 1.1–1.3; p<0.001) had a higher risk of TIIIEL. Likewise, the use of three or more endograft components increased the risk of TIIIEL by 3.1 times (SHR 3.1; 95% CI 1.7–5.4; p<0.001). Conclusions: The occurrence of TIIIELs was not affected by the type of endograft fixation. For larger abdominal aortic aneurysms (AAAs) and aneurysms with angulated and calcified aortic necks, there is a higher likelihood of developing TIIIELs during follow-up, regardless of the endograft type used. Clinical Impact: The type of fixation does not influence the incidence of TIII ELs. EVAR in larger AAAs and aneurysms with angulated and calcified aortic necks have a higher risk of developing TIII EL. Moreover, the risk of TIII EL is considerably increased by the use of three or more modular components.
- 26 December 2023
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 79 (5) , 1026-1033
Comparison of bridging stent grafts in branched endovascular aortic repair
- 26 December 2023
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 79 (5) , 1026-1033
Comparison of bridging stent grafts in branched endovascular aortic repair
- 22 December 2023
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 79 (5) , 997-1004.e1
Comparison of bare and nonbare stent grafts during thoracic endovascular aneurysm repair of the aortic arch
- 22 December 2023
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 79 (5) , 997-1004.e1
Comparison of bare and nonbare stent grafts during thoracic endovascular aneurysm repair of the aortic arch
- 11 October 2023
- Published by SAGE Publications in Angiology
- Vol. 76 (1) , 85-93
Twenty-Five Year Multicentre Experience of Explantation of Infected Abdominal Aortic Endografts
We report a multicenter experience of open conversions (OC) for aortic endograft infections (AEI). We retrospectively analyzed all patients who underwent OC for AEI after endovascular aneurysm repair (EVAR), from 1997 to 2021 in 12 Italian centers. The endpoints were as follows: mortality (30-days, in-hospital), major postoperative complications. Follow-up data included: survival, aortic-related complications, infection persistence or reoccurrence. Fifty-eight patients (mean age: 73.8 ± 6.6 years) were included. Median time from EVAR to OC was 14 months (interquartile range 7–45). Thirty-five patients (60.3%) were symptomatic at presentation. Aortic reconstruction was anatomic in 32 patients (55.2%), extra-anatomic in 26 (44.8%). Thirty-day mortality was 31% (18/58). Six additional patients died after 30 days during the same hospitalization (in-hospital mortality: 41.4%). Most common post-operative complications included respiratory failure (38.6%) and renal insufficiency (35.1%). During 28.1 ± 4 months follow-up, 4 aneurysm-related deaths were recorded. Infection re-occurred in 29.4% of the patients. Estimated survival was 50% at 1 year, and 30% at 5 years, and was significantly lower for patients who underwent extra-anatomic reconstructions (37 vs 61% at 1 year, 16 vs 45% at 5 years; log-rank P = .021). OC for AEI is associated with high early mortality. The poor mid-term survival is influenced by aortic complications and infection re-occurrence.
- 11 October 2023
- Published by SAGE Publications in Angiology
- Vol. 76 (1) , 85-93
Twenty-Five Year Multicentre Experience of Explantation of Infected Abdominal Aortic Endografts
We report a multicenter experience of open conversions (OC) for aortic endograft infections (AEI). We retrospectively analyzed all patients who underwent OC for AEI after endovascular aneurysm repair (EVAR), from 1997 to 2021 in 12 Italian centers. The endpoints were as follows: mortality (30-days, in-hospital), major postoperative complications. Follow-up data included: survival, aortic-related complications, infection persistence or reoccurrence. Fifty-eight patients (mean age: 73.8 ± 6.6 years) were included. Median time from EVAR to OC was 14 months (interquartile range 7–45). Thirty-five patients (60.3%) were symptomatic at presentation. Aortic reconstruction was anatomic in 32 patients (55.2%), extra-anatomic in 26 (44.8%). Thirty-day mortality was 31% (18/58). Six additional patients died after 30 days during the same hospitalization (in-hospital mortality: 41.4%). Most common post-operative complications included respiratory failure (38.6%) and renal insufficiency (35.1%). During 28.1 ± 4 months follow-up, 4 aneurysm-related deaths were recorded. Infection re-occurred in 29.4% of the patients. Estimated survival was 50% at 1 year, and 30% at 5 years, and was significantly lower for patients who underwent extra-anatomic reconstructions (37 vs 61% at 1 year, 16 vs 45% at 5 years; log-rank P = .021). OC for AEI is associated with high early mortality. The poor mid-term survival is influenced by aortic complications and infection re-occurrence.
- 25 April 2023
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 32 (1) , 159-169
Anatomical Feasibility of an Off-the-shelf Single-Renal Scalloped Stent-Graft for Hostile Neck Abdominal Aortic Aneurysm: A Preclinical Study
Objectives: To evaluate the feasibility of a standardized single-renal scallop stent-graft. Design: Preclinical, single-center, real-world, all-comers, retrospective cohort study. Methods: A total of 1347 abdominal aortic aneurysm (AAA) repairs (endovascular and open) performed between 2010 and 2020 were screened for elective treatment and retrievable preoperative high-quality computed tomography angiography (CTA) performed <6 months of the surgical procedure. Six hundred of the included CTAs involved prespecified measurements and a morphological assessment protocol (NCT05150873). The proximal sealing zones suitable for standard stent-graft implantations were further analyzed (N=547). The primary outcome assessed the feasibility of 2 single-renal scallop designs (10×10 mm and 15×10 mm, height × width). The feasibility was the inter-renal length ≥10 mm and ≥15 mm for prototypes #10 and #15, respectively. The secondary outcome quantified hypothetical length and surface improvements comparing those suitable for investigational devices implantation (study group) versus those not (control group). Results: Of the total, 24.7% (n=135) was feasible with prototype #10. The study versus control group sealing zones were shorter (p=0.008), with a smaller surface (p=0.009) and a higher alpha angle (p=0.039). The length and surface area increased by about 25% and 23%, respectively, (both p<0.001) within the study group and became significantly better versus the control group (standard stent-graft; both p<0.001). Of the total, 7.1% (n=39) was suitable for prototype #15. The study versus control group sealing zones were shorter (p=0.148), with a smaller surface (p=0.077) and a higher alpha angle (p=0.027). The length and surface area increased by about 34% and 31%, respectively, (both p<0.001) within the study group and became significantly higher versus the control group (standard stent-graft; both p<0.001). Conclusions: The use of single-renal scalloped stent-graft might be feasible in a considerable number of AAA patients. The breakthrough stands in treating hostile AAAs presenting in mismatched renal arteries, keeping the complexity of the repair as similar as possible to standard endovascular repair with a remarkable improvement in sealing. Clinical Impact: The anatomic feasibility of a single renal stent graft for the treatment of “hostile” abdominal aortic aneurysm (AAA) with mismatched renal arteries was evaluated. The experimental device could be feasible in a considerable number of patients with AAA, approaching 25%, and demonstrate significant improvements in sealing. As far as we know, this is the first paper to report the prevalence of mismatched renal arteries in a large cohort of AAA patients in the real world, while proposing a dedicated device. The breakthrough is to keep the complexity of the repair as close as possible to standard endovascular repair
- 25 April 2023
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 32 (1) , 159-169
Anatomical Feasibility of an Off-the-shelf Single-Renal Scalloped Stent-Graft for Hostile Neck Abdominal Aortic Aneurysm: A Preclinical Study
Objectives: To evaluate the feasibility of a standardized single-renal scallop stent-graft. Design: Preclinical, single-center, real-world, all-comers, retrospective cohort study. Methods: A total of 1347 abdominal aortic aneurysm (AAA) repairs (endovascular and open) performed between 2010 and 2020 were screened for elective treatment and retrievable preoperative high-quality computed tomography angiography (CTA) performed <6 months of the surgical procedure. Six hundred of the included CTAs involved prespecified measurements and a morphological assessment protocol (NCT05150873). The proximal sealing zones suitable for standard stent-graft implantations were further analyzed (N=547). The primary outcome assessed the feasibility of 2 single-renal scallop designs (10×10 mm and 15×10 mm, height × width). The feasibility was the inter-renal length ≥10 mm and ≥15 mm for prototypes #10 and #15, respectively. The secondary outcome quantified hypothetical length and surface improvements comparing those suitable for investigational devices implantation (study group) versus those not (control group). Results: Of the total, 24.7% (n=135) was feasible with prototype #10. The study versus control group sealing zones were shorter (p=0.008), with a smaller surface (p=0.009) and a higher alpha angle (p=0.039). The length and surface area increased by about 25% and 23%, respectively, (both p<0.001) within the study group and became significantly better versus the control group (standard stent-graft; both p<0.001). Of the total, 7.1% (n=39) was suitable for prototype #15. The study versus control group sealing zones were shorter (p=0.148), with a smaller surface (p=0.077) and a higher alpha angle (p=0.027). The length and surface area increased by about 34% and 31%, respectively, (both p<0.001) within the study group and became significantly higher versus the control group (standard stent-graft; both p<0.001). Conclusions: The use of single-renal scalloped stent-graft might be feasible in a considerable number of AAA patients. The breakthrough stands in treating hostile AAAs presenting in mismatched renal arteries, keeping the complexity of the repair as similar as possible to standard endovascular repair with a remarkable improvement in sealing. Clinical Impact: The anatomic feasibility of a single renal stent graft for the treatment of “hostile” abdominal aortic aneurysm (AAA) with mismatched renal arteries was evaluated. The experimental device could be feasible in a considerable number of patients with AAA, approaching 25%, and demonstrate significant improvements in sealing. As far as we know, this is the first paper to report the prevalence of mismatched renal arteries in a large cohort of AAA patients in the real world, while proposing a dedicated device. The breakthrough is to keep the complexity of the repair as close as possible to standard endovascular repair